Volume 22, Issue 1 (January-February 2023)
Payesh 2023, 22(1): 105-108 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Behboudi E, Ebrahimian A, Zeynali P. The emergence of new variants and sub-variants of SARS-CoV-2 and the effectiveness of vaccines. Payesh 2023; 22 (1) :105-108
URL: http://payeshjournal.ir/article-1-2061-en.html
URL: http://payeshjournal.ir/article-1-2061-en.html
1- Department of Basic Sciences, Khoy University of Medical Sciences, Khoy, Iran
2- Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran
2- Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran
Abstract: (931 Views)
Dear Editor,
At the end of 2020, variants of the SARS-CoV-2 virus appeared as a great risk to public’s health and therefore, in order to prioritize global monitoring and research, they were placed in the category of variants of interest (VOIs), variants of concern (VOCs) and under monitoring variants (VUMs). As of April 2022, omicron (B.1.1.529) sub-variants of SARS-CoV-2, including BA.2.12.1, BA.4, and BA.5, are considered variants of concern with increased virulence and transmissibility. The omicron variant of SARS-CoV-2 is emerging in communities where people have already been infected with earlier variants and are now vaccinated, or people who have received two or three doses of the coronavirus vaccination. More than 130 countries worldwide have implemented booster programs to combat omicron. Despite preliminary findings that suggest booster doses may improve omicron protection, more research is needed to prove this. In the case of the COVID-19, it was recommended that at least 2 injections of the vaccine be given, and after 6 months we saw a decline in immunity. Taken together, the studies suggest that the BQ and XBB subtypes pose serious threats to current vaccines, inactivate all neutralizing antibodies, and may have spread in the population due to their evolution in evading antibodies. Though people still need to take this issue seriously and protect themselves.
At the end of 2020, variants of the SARS-CoV-2 virus appeared as a great risk to public’s health and therefore, in order to prioritize global monitoring and research, they were placed in the category of variants of interest (VOIs), variants of concern (VOCs) and under monitoring variants (VUMs). As of April 2022, omicron (B.1.1.529) sub-variants of SARS-CoV-2, including BA.2.12.1, BA.4, and BA.5, are considered variants of concern with increased virulence and transmissibility. The omicron variant of SARS-CoV-2 is emerging in communities where people have already been infected with earlier variants and are now vaccinated, or people who have received two or three doses of the coronavirus vaccination. More than 130 countries worldwide have implemented booster programs to combat omicron. Despite preliminary findings that suggest booster doses may improve omicron protection, more research is needed to prove this. In the case of the COVID-19, it was recommended that at least 2 injections of the vaccine be given, and after 6 months we saw a decline in immunity. Taken together, the studies suggest that the BQ and XBB subtypes pose serious threats to current vaccines, inactivate all neutralizing antibodies, and may have spread in the population due to their evolution in evading antibodies. Though people still need to take this issue seriously and protect themselves.
Subject:
Public Health
Received: 2023/01/24 | Accepted: 2023/01/29 | ePublished ahead of print: 2023/02/6 | Published: 2023/02/7
Received: 2023/01/24 | Accepted: 2023/01/29 | ePublished ahead of print: 2023/02/6 | Published: 2023/02/7
References
1. Chavda VP, Apostolopoulos V. Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2? Vaccines 2022;10:367 [DOI:10.3390/vaccines10030367]
2. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. New England Journal of Medicine 2022;387:21-34 [DOI:10.1056/NEJMoa2203965]
3. Chavda VP, Vora LK, Pandya AK, Patravale VB. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug discovery today 2021; 26:2619-36 [DOI:10.1016/j.drudis.2021.07.021]
4. Chavda VP, Vora LK, Vihol DR. COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals. Clinical Complementary Medicine and Pharmacology 2021;1:100004 [DOI:10.1016/j.ccmp.2021.100004]
5. Chavda VP, Kapadia C, Soni S, Prajapati R, Chauhan SC, Yallapu MM, et al. A global picture: therapeutic perspectives for COVID-19. Immunotherapy 2022;14:351-71 [DOI:10.2217/imt-2021-0168]
6. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature medicine 2021;27:270-8 [DOI:10.1038/s41591-020-01194-5]
7. Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 2023;186: 279-286.e8 [DOI:10.1016/j.cell.2022.12.018]
8. Behboudi E, Shamsi A, Hamidi-Sofiani V, Oladnabi M. The effects of fasting in Ramadan on the risk factors of COVID-19 in adolescents: a brief review. International Journal of Pediatrics 2021;9:12835-42
9. Emadi, M.S., Soltani, S., Noori, B., Zandi, M., Shateri, Z., Tabibzadeh, A., Behboudi, E., Erfani, Y., Tabaeian, S.P., Pourhossein, B. and Didehdar, M. Highly Conserve Sequences in Envelope, Nucleoprotein and RNA-Dependent RNA Polymerase of SARS-CoV-2 in Nasopharyngeal Samples of the COVID-19 Patients; a Diagnostic Target for Further Studies. Journal of Cellular & Molecular Anesthesia 2022;7:78-83
10. Ayatollahi AA, Aghcheli B, Amini A, Nikbakht H, Ghassemzadehpirsala P, Behboudi E, Rajabi A, Tahamtan A. Association between blood groups and COVID-19 outcome in Iranian patients. Future Virology 2021;16:657-65 [DOI:10.2217/fvl-2021-0090]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |